KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Royalty Pharma (RPRX) Return on Equity (2020 - 2025)

Royalty Pharma's Return on Equity history spans 6 years, with the latest figure at 0.14% for Q4 2025.

  • For Q4 2025, Return on Equity rose 1.0% year-over-year to 0.14%; the TTM value through Dec 2025 reached 0.14%, up 1.0%, while the annual FY2025 figure was 0.13%, 0.0% changed from the prior year.
  • Return on Equity for Q4 2025 was 0.14% at Royalty Pharma, up from 0.14% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.19% in Q2 2021 and bottomed at 0.02% in Q4 2022.
  • The 5-year median for Return on Equity is 0.12% (2021), against an average of 0.12%.
  • The largest annual shift saw Return on Equity fell -14bps in 2021 before it increased 15bps in 2023.
  • A 5-year view of Return on Equity shows it stood at 0.12% in 2021, then tumbled by -81bps to 0.02% in 2022, then skyrocketed by 649bps to 0.17% in 2023, then decreased by -25bps to 0.13% in 2024, then grew by 6bps to 0.14% in 2025.
  • Per Business Quant, the three most recent readings for RPRX's Return on Equity are 0.14% (Q4 2025), 0.14% (Q3 2025), and 0.17% (Q2 2025).